Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606966 | 1.00 | CA12 (0.52) | CA12CA1CA2CA9GRM3 | |
| SCHEMBL20738739 | 1.00 | CA12 (0.52) | CA12CA1CA2CA9GRM3 | |
| SCHEMBL21023431 | 0.94 | CA12 (0.46) | CA12CA1CA2CA9GRM3 | |
| SCHEMBL524200 | 0.94 | CA12 (0.46) | CA12CA1CA2CA9GRM3 | |
| SCHEMBL50397 | 0.86 | — | — | |
| SCHEMBL524422 | 0.86 | — | — | |
| SCHEMBL4513056 | 0.86 | — | — | |
| SCHEMBL524353 | 0.83 | EPHX2 (0.47) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL17457507 | 0.82 | CA12 (0.55) | CA12CA1CA2CA9GRM3 | |
| SCHEMBL27924788 | 0.82 | CA12 (0.55) | CA12CA1CA2CA9GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2022212296-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7226942-B2 | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226942-B2 | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7176222-B2 | Syntheses of ureas | CYTOKINETICS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176222-B2 | Syntheses of ureas | CYTOKINETICS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176222-B2 | Syntheses of ureas | CYTOKINETICS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060025470-A1 | Contacting a base with an enantiomerically pure hydroxyl group containing compound, reacting the product with a nitro, fluoro-containing benzene compound, reducing the product to the corresponding amine | CYTOKINETICS, INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
| WO-2004064730-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | CA12 3975/4885CA1 3792/4885CA2 1845/4885 |
| US-20060025470-A1 | Contacting a base with an enantiomerically pure hydroxyl group containing compound, reacting the product with a nitro, fluoro-containing benzene compound, reducing the product to the corresponding amine | NPM1, FUS, DNPH1 | CA12 1251/4885CA1 392/4885CA2 1479/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | CA12 3975/4885CA1 3792/4885CA2 1845/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | CA12 4116/4885CA1 3915/4885CA2 1947/4885 |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | CA12 1882/4885CA1 640/4885CA2 264/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | CA12 3975/4885CA1 3792/4885CA2 1845/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | CA12 4120/4885CA1 2044/4885CA2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.